System to be Installed in One of Canada's Largest Academic Cancer Centers
SUNNYVALE, Calif., June 26 /CNW/ -- Accuray Incorporated (Nasdaq: ARAY),
a global leader in the field of radiosurgery today announced that Centre
Hospitalier de l'Universite de Montreal (CHUM) has purchased a CyberKnife(R)
Robotic Radiosurgery System for installation at Hopital Notre- Dame du CHUM,
in Montreal, Canada.
CHUM, one of the largest radiation oncology centers in Canada, will
utilize the CyberKnife System to treat both intracranial and extracranial
tumors including those in the lung, spine and prostate.
CHUM is one of the leading academic sites in North America for the number
of accruals for protocols developed by the Radiation Therapy Oncology Group
(RTOG) of the American College of Radiology (ACR), demonstrating the center's
leadership in research and innovation.
"In addition to being an important purchase for the people of Canada, the
addition of a CyberKnife System at CHUM provides an opportunity for continued
research and clinical investigation," said Euan S. Thomson, Ph.D., president
and CEO of Accuray. "We are thrilled to be working with such a reputable
teaching facility that's had continued success in accruing patients under
In Quebec, authorization is required from a regional authority to acquire
certain medical technologies, such as imaging and radiation therapy. CHUM
secured approval in May 2008 and plans to install its CyberKnife System by
The Centre hospitalier de l'Universite de Montreal provides specialized
and ultra-specialized services to a regional and supra-regional clientele.
Within its more immediate coverage area, the CHUM also provides general and
specialized hospital care and services. The CHUM uses an integrated network
model to carry out its five-part mandate of care, teaching, research, the
assessment of technologies and health care methodologies, and the promotion of
health care. Through its determined efforts to continuously improve quality of
care and patient safety, the CHUM has again received accreditation from the
Canadian Council on Health Services Accreditation, for the 2007-2010 period.
Hotel-Dieu, Hopital Notre-Dame, and Hopital Saint-Luc make up the CHUM, with
approximately 10,000 employees, 900 physicians, 270 researchers, 6,000
students and trainees and 700 volunteers providing services to over a million
patients each year. www.chumontreal.qc.ca.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body non-
invasively. Using continual image guidance technology and computer controlled
robotic mobility, the CyberKnife System automatically tracks, detects and
corrects for tumor and patient movement in real-time throughout the treatment.
This enables the CyberKnife System to deliver high-dose radiation with
pinpoint precision, which minimizes damage to surrounding healthy tissue and
eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 40,000 patients
worldwide and currently more than 130 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more information, please visit
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, clinical studies, regulatory review
and approval, and market acceptance and commercialization of products and
services are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements speak only as of the date the statements are made
and are based on information available at the time those statements are made
and/or management's good faith belief as of that time with respect to future
events. You should not put undue reliance on any forward-looking statements.
Important factors that could cause actual performance and results to differ
materially from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our products
with complementary technology; and other risks detailed from time to time
under the heading "Risk Factors" in our report on Form 10-K for the 2007
fiscal year, as updated from time to time by our quarterly reports on Form 10-
Q and our other filings with the Securities and Exchange Commission. The
Company's actual results of operations may differ significantly from those
contemplated by such forward-looking statements as a result of these and other
factors. We assume no obligation to update forward-looking statements to
reflect actual performance or results, changes in assumptions or changes in
other factors affecting forward-looking information, except to the extent
required by applicable securities laws.
For further information:
For further information: Susan Lehman of Rockpoint Public Relations,
+1-510-832-6006, firstname.lastname@example.org, for Accuray Incorporated; or
Stephanie Tomei, Public Relations Manager of Accuray Incorporated,
+1-408-789-4234, email@example.com Web Site: http://www.accuray.com